Nektar Therapeutics Announces Conference Call for REZOLVE-AD Results

Nektar Therapeutics, a biotechnology company based in San Francisco, will host a conference call on February 10, 2026, to discuss topline results from the 36-week maintenance period of its Phase 2b clinical trial for Rezpegaldesleukin. This investigational therapy targets moderate-to-severe atopic dermatitis and represents a significant step in the company’s research into novel immunology therapies.

The conference call is scheduled for 08:00 ET / 05:00 PT. Participants can join the call via a live webcast, which will also feature a presentation of the results. A press release detailing the findings will be made available in the morning, prior to the event.

Nektar’s development of Rezpegaldesleukin, also known as REZPEG or NKTR-358, is part of a broader effort to address autoimmune and chronic inflammatory diseases. This therapy functions as a regulatory T-cell (Treg) proliferator, potentially offering new hope for patients suffering from atopic dermatitis.

Event Details and Access Information

Interested individuals can access the live webcast through a link provided by Nektar. The event, along with the press materials and presentation slides, will also be available in the events section of Nektar’s website. A recorded version of the webcast will remain accessible for at least 30 days post-event.

Nektar is actively advancing Rezpegaldesleukin through multiple clinical trials. In addition to the ongoing studies in atopic dermatitis, the company is also evaluating this treatment in alopecia areata and Type 1 diabetes mellitus.

Nektar’s Broader Pipeline

Beyond Rezpegaldesleukin, Nektar is developing several other promising therapies. This includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, namely NKTR-0165 and NKTR-0166. Additionally, the company is working on a modified hematopoietic colony stimulating factor protein, NKTR-422.

Together with partners, Nektar is also investigating NKTR-255, an IL-15 receptor agonist aimed at enhancing the immune system’s ability to combat cancer. These efforts reflect Nektar’s commitment to advancing innovative therapies for a range of serious health conditions.

For further inquiries, investors can contact Vivian Wu at 628-895-0661 or via email at [email protected]. Media representatives may reach out to Jonathan Pappas at LifeSci Communications at 857-205-4403 or [email protected].

As Nektar prepares to share these important findings, the biotechnology community will be closely watching for insights into the efficacy of Rezpegaldesleukin in treating atopic dermatitis, a condition impacting millions worldwide. This conference call marks a critical moment for both Nektar and the patients who may benefit from its innovative therapies.